Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.56 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.53 | |||||
| Debt-to-EBITDA | -0.34 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -9.28 | |||||
| Beneish M-Score | -3.23 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.1 | |||||
| 3-Year EBITDA Growth Rate | 7.4 | |||||
| 3-Year EPS without NRI Growth Rate | 7.9 | |||||
| 3-Year FCF Growth Rate | 6.6 | |||||
| 3-Year Book Growth Rate | -37.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | -2.64 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.46 | |||||
| 9-Day RSI | 33.37 | |||||
| 14-Day RSI | 34.63 | |||||
| 6-1 Month Momentum % | -71.87 | |||||
| 12-1 Month Momentum % | -77.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.2 | |||||
| Quick Ratio | 7.86 | |||||
| Cash Ratio | 7.63 | |||||
| Days Inventory | 283.64 | |||||
| Days Sales Outstanding | 49.91 | |||||
| Days Payable | 146.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.68 | |||||
| Operating Margin % | -182.56 | |||||
| Net Margin % | -467 | |||||
| ROE % | -99.41 | |||||
| ROA % | -52.65 | |||||
| ROIC % | -75.17 | |||||
| ROC (Joel Greenblatt) % | -354.31 | |||||
| ROCE % | -54.59 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.26 | |||||
| PB Ratio | 0.47 | |||||
| Price-to-Tangible-Book | 0.47 | |||||
| EV-to-EBIT | 0.56 | |||||
| EV-to-EBITDA | 0.58 | |||||
| EV-to-Revenue | -2.42 | |||||
| EV-to-Forward-Revenue | 1.52 | |||||
| EV-to-FCF | 0.8 | |||||
| Price-to-Median-PS-Value | 0.11 | |||||
| Price-to-Net-Current-Asset-Value | 0.67 | |||||
| Price-to-Net-Cash | 0.84 | |||||
| Earnings Yield (Greenblatt) % | 178.57 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NKTR
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 88.827 | ||
| EPS (TTM) ($) | -2.21 | ||
| Beta | 0.68 | ||
| Volatility % | 82.66 | ||
| 14-Day RSI | 34.63 | ||
| 14-Day ATR ($) | 0.047633 | ||
| 20-Day SMA ($) | 0.66218 | ||
| 12-1 Month Momentum % | -77.51 | ||
| 52-Week Range ($) | 0.5801 - 5.18 | ||
| Shares Outstanding (Mil) | 189.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nektar Therapeutics Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nektar Therapeutics Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(NKTR)'s stock price today?
The current price of NKTR is $0.60. The 52 week high of NKTR is $5.18 and 52 week low is $0.58.
When is next earnings date of Nektar Therapeutics(NKTR)?
The next earnings date of Nektar Therapeutics(NKTR) is 2023-08-04 Est..
Does Nektar Therapeutics(NKTR) pay dividends? If so, how much?
Nektar Therapeutics(NKTR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers